Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Academic Article
Publication Date:
2021
abstract:
Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
Iris type:
1.1 Articolo in rivista
List of contributors:
Byrd, John C; Hillmen, Peter; Ghia, Paolo; Kater, Arnon P; Chanan-Khan, Asher; Furman, Richard R; O'Brien, Susan; Yenerel, Mustafa Nuri; Illés, Arpad; Kay, Neil; Garcia-Marco, Jose A; Mato, Anthony; Pinilla-Ibarz, Javier; Seymour, John F; Lepretre, Stephane; Stilgenbauer, Stephan; Robak, Tadeusz; Rothbaum, Wayne; Izumi, Raquel; Hamdy, Ahmed; Patel, Priti; Higgins, Kara; Sohoni, Sophia; Jurczak, Wojciech
Published in: